Cell Source, Inc. (CLCS)
USD 0.5
(0.0%)
USD 0.5
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.27 Million USD | 43.31% |
| 2022 | -4.17 Million USD | -5.21% |
| 2021 | - USD | -9.09% |
| 2020 | - USD | 9.71% |
| 2019 | - USD | -83.36% |
| 2018 | -2 Million USD | 35.5% |
| 2017 | -2.29 Million USD | 4.19% |
| 2016 | -3.55 Million USD | -53.31% |
| 2015 | -2.31 Million USD | 42.79% |
| 2014 | -4.05 Million USD | -15720.37% |
| 2013 | -25.62 Thousand USD | -526646.13% |
| 2012 | 4.87 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.13 Million USD | 100.0% |
| 2024 Q2 | -1.19 Million USD | 0.0% |
| 2023 Q3 | -995.38 Thousand USD | -9.93% |
| 2023 FY | - USD | -0.18% |
| 2023 Q4 | -866.35 Thousand USD | 12.96% |
| 2023 Q1 | -1.41 Million USD | -31.96% |
| 2023 Q2 | -905.46 Thousand USD | 36.03% |
| 2022 Q2 | -1.03 Million USD | 1.79% |
| 2022 FY | - USD | -5.21% |
| 2022 Q3 | -1.01 Million USD | 1.72% |
| 2022 Q1 | -1.05 Million USD | -79.4% |
| 2022 Q4 | -1.07 Million USD | -5.58% |
| 2021 Q4 | -586.78 Thousand USD | 55.39% |
| 2021 FY | - USD | -9.09% |
| 2021 Q2 | -995.09 Thousand USD | 7.12% |
| 2021 Q3 | -1.31 Million USD | -32.18% |
| 2021 Q1 | -1.07 Million USD | -10.65% |
| 2020 Q4 | -968.23 Thousand USD | 6.28% |
| 2020 Q1 | -733.33 Thousand USD | -56.84% |
| 2020 Q2 | -903.33 Thousand USD | -23.18% |
| 2020 FY | - USD | 9.71% |
| 2020 Q3 | -1.03 Million USD | -14.37% |
| 2019 FY | - USD | -83.36% |
| 2019 Q1 | -1.43 Million USD | -129.46% |
| 2019 Q2 | -691.48 Thousand USD | 51.76% |
| 2019 Q3 | -1.43 Million USD | -107.77% |
| 2019 Q4 | -467.56 Thousand USD | 67.46% |
| 2018 Q2 | -423.9 Thousand USD | 35.78% |
| 2018 FY | - USD | 35.5% |
| 2018 Q4 | -624.72 Thousand USD | -27.85% |
| 2018 Q3 | -488.64 Thousand USD | -15.27% |
| 2018 Q1 | -660.11 Thousand USD | 33.77% |
| 2017 Q1 | -1.19 Million USD | 32.91% |
| 2017 Q3 | -555.13 Thousand USD | 33.72% |
| 2017 Q2 | -837.62 Thousand USD | 29.86% |
| 2017 FY | - USD | 4.19% |
| 2017 Q4 | -996.66 Thousand USD | -79.53% |
| 2016 Q1 | -644.46 Thousand USD | -4.43% |
| 2016 Q2 | -529.95 Thousand USD | 17.77% |
| 2016 FY | - USD | -53.31% |
| 2016 Q3 | -601.52 Thousand USD | -13.51% |
| 2016 Q4 | -1.78 Million USD | -195.94% |
| 2015 FY | - USD | 42.79% |
| 2015 Q4 | -617.12 Thousand USD | -12.42% |
| 2015 Q3 | -548.92 Thousand USD | 3.28% |
| 2015 Q1 | -618.62 Thousand USD | 60.07% |
| 2015 Q2 | -567.51 Thousand USD | 8.26% |
| 2014 Q1 | -11.89 Thousand USD | 29.06% |
| 2014 Q3 | -715.08 Thousand USD | 29.7% |
| 2014 Q2 | -1.01 Million USD | -8449.15% |
| 2014 FY | - USD | -15720.37% |
| 2014 Q4 | -1.54 Million USD | -116.66% |
| 2013 Q4 | -16.77 Thousand USD | -614.35% |
| 2013 Q3 | -2348.00 USD | 99.53% |
| 2013 Q2 | -496.28 Thousand USD | -10209.29% |
| 2013 FY | - USD | -526646.13% |
| 2013 Q1 | -4814.00 USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | -24.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 93.985% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 27.937% |
| SQZ Biotechnologies Company | -64.14 Million USD | 93.339% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 75.403% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 104.543% |
| Mesoblast Limited | -62.38 Million USD | 93.152% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -178.15% |
| Genus plc | 73.7 Million USD | 105.797% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 35.378% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -20.455% |
| Marizyme, Inc. | -34.28 Million USD | 87.537% |
| ContraFect Corporation | -64.99 Million USD | 93.427% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 51.294% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 5.604% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -204.787% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -61.566% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -83.858% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -724.739% |
| Accustem Sciences Inc. | -3.74 Million USD | -14.043% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 91.141% |
| EV Biologics, Inc. | -1.26 Million USD | -237.181% |
| Q BioMed Inc. | -617.62 Thousand USD | -591.764% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 219.612% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -575.599% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -87.023% |
| Biomind Labs Inc. | -1.03 Million USD | -312.984% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 143.257% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 40.338% |
| Skye Bioscience, Inc. | -13.54 Million USD | 68.463% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -187.246% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -16990.104% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -9.994% |
| IMV Inc. | -35.52 Million USD | 87.973% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 73.078% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -70.767% |
| GB Sciences, Inc. | -1.41 Million USD | -200.906% |
| Alpha Cognition Inc. | -9.7 Million USD | 55.979% |
| HST Global, Inc. | -5303.00 USD | -80468.094% |
| CSL Limited | 4.78 Billion USD | 100.089% |
| Halberd Corporation | -74.27 Thousand USD | -5651.997% |
| Enzolytics Inc. | -2.12 Million USD | -101.342% |
| Resverlogix Corp. | -11.74 Million USD | 63.613% |
| Affymax, Inc. | -14.29 Million USD | 70.112% |
| SYBLEU INC | -141.57 Thousand USD | -2917.939% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -39.488% |
| argenx SE | -216.02 Million USD | 98.022% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 92.279% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 451.07% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -185.043% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1227.78% |
| AVAX Technologies, Inc. | -6.11 Million USD | 30.103% |
| Zenith Capital Corp. | -8.6 Million USD | 50.354% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.282% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -24425.148% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -74.641% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2327.236% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 89.221% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -47.719% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -308.341% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 63641.434% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -144.144% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -122.422% |
| BioStem Technologies, Inc. | -7.55 Million USD | 43.438% |
| ONE Bio Corp. | 13.61 Million USD | 131.386% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2259.365% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -107.707% |
| Agentix Corp. | -1.37 Million USD | -211.464% |
| LadRx Corporation | 412.28 Thousand USD | 1136.309% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1063.475% |
| Regen BioPharma, Inc. | 1.46 Million USD | 391.45% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -356.004% |
| NovAccess Global Inc. | -1.03 Million USD | -312.885% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 148.256% |
| Itoco Inc. | -1.86 Million USD | -128.6% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1025.474% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -282.843% |
| Kadimastem Ltd | -2.62 Million USD | -62.801% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1686.547% |
| CytoDyn Inc. | -18.02 Million USD | 76.302% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -5306.276% |
| Mobile Lads Corp. | -2.24 Million USD | -90.639% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -34837.656% |
| Qrons Inc. | -40.08 Thousand USD | -10559.729% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -779.703% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 910.06% |
| Rebus Holdings, Inc. | -951 Thousand USD | -349.267% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -302.306% |
| International Stem Cell Corporation | 202 Thousand USD | 2215.112% |
| Bioxytran, Inc. | -3.82 Million USD | -11.842% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8016.501% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -73.544% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 88.089% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -9394.502% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -56.046% |
| Neutra Corp. | -181.24 Thousand USD | -2257.295% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 78.806% |
| PureTech Health plc | -11.62 Million USD | 63.253% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 78.804% |
| IXICO plc | -707 Thousand USD | -504.318% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 44.404% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 91.163% |
| CSL Limited | 4.73 Billion USD | 100.09% |
| Cellectis S.A. | -92.63 Million USD | 95.388% |